Pharmacy Times

JUNE 17, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Mail-Order Pharmacies 29

Mail-Order Pharmacies Pharmacy Technician Compounding Pharmacies Inpatient 29

Pharmacy Times

JUNE 23, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Pharmacy Times

JUNE 20, 2025

Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. It was approved last year.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Immunization Immunity 26

Pharmacy Times

JUNE 25, 2025

months versus 7.79 months with tislelizumab. months versus 7.79 months with tislelizumab. months versus 7.79 months with tislelizumab.

Chemotherapy 20

Chemotherapy Pharmacy Technician Immunization Immunity 20

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

Inpatient 29

Inpatient HIV Treatment and Prevention Agents Pharmacy Technician Chemotherapy 29

Pharmacy Times

JULY 9, 2025

SHOW MORE Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.

Pharmacy Technician 34

Pharmacy Technician Immunization Immunity Compounding Pharmacies 34

Pharmacy Times

JUNE 20, 2025

For effective patient care, we need smart people to design workflows for operationalizing 505(b)(2) drugs, integrating the next biosimilar we have to stock, and managing the compounding of a new hazardous drug. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.

Pharmacy Technician 46

Pharmacy Technician Compounding Compounding Pharmacies Biosimilars 46

Pharmacy Times

JUNE 10, 2025

Related Videos Related Content Advertisement June 10th 2025 Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems Aislinn Antrim, Managing Editor June 3rd 2025 S2. December 21, 2004. Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician HIV Treatment and Prevention Agents Compounding Pharmacies Biosimilars 29

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management 29

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So there’s things in the pipeline that are being developed with novel conjugated agents, such as radiopharmaceuticals, immune-activating agents like STING agents, PROTACs. Unfortunately, these drugs are quite toxic.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Pharmacies Immunization 26

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage 26

Dosage Pharmacy Technician Compounding Pharmacies Inpatient 26

Pharmacy Times

JUNE 19, 2025

Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 20

Pharmacy Times

JUNE 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Chemotherapy 26

Chemotherapy Pharmacy Technician Immunization Immunity 26

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy 56

Chemotherapy Pharmacy Technician Immunization Immunity 56

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. For both trials, the major efficacy outcomes were confirmed overall response rate (cORR) and duration of response (DOR).

Pharmacy Technician 29

Pharmacy Technician Biosimilars Compounding Pharmacies Pharmacy Management 29

Pharmacy Times

JULY 3, 2025

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

Inpatient 26

Inpatient Pharmacy Technician Specialty Pharmacies Compounding Pharmacies 26

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Pharmacy Technician 22

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 22

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy.

Pharmacy Technician 26

Pharmacy Technician Chemotherapy Compounding Pharmacies Pharmacy Management 26

Pharmacy Times

JUNE 25, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 29

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 29

Pharmacy Times

JUNE 19, 2025

EGFR and ALK mutations are significant targets, with osimertinib and alectinib showing improved outcomes in early-stage NSCLC trials.

Chemotherapy 29

Chemotherapy Pharmacy Technician Compounding Pharmacies Hospitals 29

Pharmacy Times

JUNE 6, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management 26

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

Pharmacy Times

JUNE 17, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Diabetes 26

Diabetes Pharmacy Technician Compounding Pharmacies Hospitals 26

Pharmacy Times

JUNE 23, 2025

NSCLC accounts for 80% of lung cancer cases, with EGFR mutations in 10% to 15% of lung adenocarcinomas. Datopotamab is a TROP-2 targeting ADC with a 45% ORR and a median DOR of 6.5

Pharmacy Technician 34

Pharmacy Technician Compounding Pharmacies Diabetes Chemotherapy 34

Pharmacy Times

JUNE 9, 2025

Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 29

pharmaphorum

JULY 18, 2025

Find out more about the event here: [link] Image 18 July, 2025 Hanson Wade Bookmark this Oncology Taking chemotherapy directly to skin lesions, with Dr Raza B. Partner Content Partner Content Unlocking the Potential of Targeting the Innate Immune Syste. Ready to Catalyze the Next Wave of Inflammasome Therapies?

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 52

pharmaphorum

DECEMBER 21, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

Quality Matters

FEBRUARY 6, 2025

To understand monoclonal antibody drugs, its necessary to first know a little about how antibodies work in the bodys immune system. The immune system protects the body from harmful substances, microbes and abnormal cells that can cause diseases. Anything that triggers an immune response is called an antigen.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Immunity Immunization Biosimilars 52

PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

Chemotherapy 40

Chemotherapy Biosimilars Immunization Immunity 40

pharmaphorum

DECEMBER 18, 2020

Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of therapy. The median progression-free survival (PFS) of patients treated with Margenza and chemotherapy was 5.8 months in patients treated with trastuzumab and chemotherapy.

Chemotherapy 52

Chemotherapy Biosimilars Immunization Immunity 52

PharmaShots

MARCH 29, 2023

Some companies accept the offered period and open doors to biological drugs or biosimilars. It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. As of now, there are no the US FDA approved biosimilars available for Actemra.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunization 49

RX Note

FEBRUARY 23, 2023

. - Drug registration number Medicines (Advertisement & Sale) Act 1956 and Regulations - To learn prohibitions of medicine advertisement and Medicine Advertisement Board Registration of Pharmacists Act 1951 and Regulations - Pharmacy Board Malaysia and legislation aspects of provisional, full and temporary registration Code of Ethics for Pharmacists (..)

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58

European Pharmaceutical Review

FEBRUARY 3, 2025

Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy. Pavblu (aflibercept) and Skojoy (aflibercept) for the treatment of neovascular age-related macular degeneration and visual impairment related to various conditions.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Biosimilars 52